ALAlphabet Inc.
Institutional investor · Portfolio as of Q4 2022
Top Holdings51 positions
PRIME MEDICINE INC | 13.3M | $246.8M | 14.3% | $18.58 | 0.00% | 1 qtr | New 95 |
VERVE THERAPEUTICS INC | 10.5M | $204.1M | 11.9% | — | — | 7 qtrssince 2021-Q2 | Decreased 0 |
UIPATH INC | 14.1M | $178.8M | 10.4% | $67.93 | -81.29% | 7 qtrssince 2021-Q2 | Unchanged 0 |
DEXCOM INC | 1.3M | $141.6M | 8.2% | $77.24 | +46.60% | 14 qtrssince 2019-Q3 | Decreased 0 |
PLANET LABS PBC | 31.9M | $139M | 8.1% | $6.15 | -29.27% | 5 qtrssince 2021-Q4 | Unchanged 0 |
EQRX Inc | 47.7M | $117.3M | 6.8% | — | — | 5 qtrssince 2021-Q4 | Increased 58 |
SNOWFLAKE INC | 535,604 | $76.9M | 4.5% | $229.13 | -37.35% | 4 qtrssince 2022-Q1 | Unchanged 0 |
CROWDSTRIKE HLDGS INC | 622,073 | $65.5M | 3.8% | $26.32 | 0.00% | 1 qtr | New 82 |
FRESHWORKS INC | 4M | $59.4M | 3.4% | $26.26 | -43.98% | 5 qtrssince 2021-Q4 | Unchanged 0 |
OSCAR HEALTH INC | 24M | $59.1M | 3.4% | $26.88 | -90.85% | 8 qtrssince 2021-Q1 | Unchanged 0 |
GITLAB INC | 1.3M | $58.8M | 3.4% | $48.97 | -7.21% | 3 qtrssince 2022-Q2 | Increased 87 |
LYFT INC | 5.3M | $57.9M | 3.4% | $40.84 | -73.02% | 14 qtrssince 2019-Q3 | Decreased 0 |
DUOLINGO INC | 704,444 | $50.1M | 2.9% | $109.82 | -35.23% | 6 qtrssince 2021-Q3 | Unchanged 0 |
ROBINHOOD MKTS INC | 4.9M | $40.1M | 2.3% | $42.08 | -80.66% | 6 qtrssince 2021-Q3 | Unchanged 0 |
Benson Hill Inc | 15.4M | $39.7M | 2.3% | — | — | 6 qtrssince 2021-Q3 | Unchanged 0 |
RELAY THERAPEUTICS INC | 1.6M | $23.4M | 1.4% | $41.71 | -64.18% | 10 qtrssince 2020-Q3 | Unchanged 0 |
LYELL IMMUNOPHARMA INC | 5.9M | $20.4M | 1.2% | $324.80 | -78.63% | 7 qtrssince 2021-Q2 | Unchanged 0 |
Desktop Metal Inc | 11M | $15M | 0.9% | — | — | 9 qtrssince 2020-Q4 | Unchanged 0 |
23ANDME HOLDING CO | 6.7M | $14.6M | 0.8% | — | — | 5 qtrssince 2021-Q4 | Unchanged 0 |
BEAM THERAPEUTICS INC | 321,604 | $12.6M | 0.7% | $18.00 | +117.28% | 12 qtrssince 2020-Q1 | Unchanged 0 |
Alphabet Inc. manages $1.7B across 51 positions as of Q4 2022. Top holdings: PRME (14.3%), VERV (11.9%), PATH (10.4%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.
Added 2 new positions, increased 2, trimmed 5. Top move: PRME (NEW, conviction 95). Portfolio: $1.7B across 51 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR